SGLT-2 & cardiovascular neural activity.

What is it about?

Many experiments and clinical trials suggest SGLT-2 could reverse the sympathetic neural overactivation, while its central effects has not been fully elucidated. In this study, we investigated the effect of SGLT-2 Inhibitor Dapagliflozin on the modulation of presympathetic neurons in the paraventricular nucleus of the hypothalamus (PVH), which revealed a pathway from the kidney to the hypothalamus, brainstem, and the sympathetic nervous system involved in cardiovascular activity.

Featured Image

Photo by Count Chris on Unsplash

Photo by Count Chris on Unsplash

Why is it important?

The pathophysiology of heart failure often highlights the critical link between chronic overactivation of the sympathetic nervous system and RAAS, including obesity, hypertension, diabetic complications, and renal impairment. Therefore, targeting central cardiovascular neural activity has become more effective and useful. Many clinical trials have suggested the therapeutic benefits of SGLT-2 inhibitors in treating chronic heart-renal-metabolic syndrome, but the central role of these agents has not been fully established. Consequently, targeting the central RAAS and sympathetic nervous system in future treatments will become more promising if the objective and functional aspects of specific neural pathways could be figured out.

Perspectives